2024-06-05 23:46:37 ET
Summary
- ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue.
- Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launch.
- ACAD has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer's disease psychosis, which could create additional revenue verticals.
- The company is developing ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer's disease psychosis.
- ACAD's strong pipeline and solid cash flow support its valuation, making it a compelling investment alternative in biotech.
...
Read the full article on Seeking Alpha
For further details see:
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments